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ABSTRACT
Dendritic cells (DCs) comprise two functionally distinct
subsets: plasmacytoid DCs (pDCs) and myeloid DCs
(mDCs). pDCs are specialized in rapid and massive se-
cretion of type I interferon (IFN-I) in response to nucleic
acids through Toll like receptor (TLR)-7 or TLR-9. In this
report, we characterized a CD56+ DC population that
express typical pDC markers including CD123 and
BDCA2 but produce much less IFN-I comparing with
pDCs. In addition, CD56+ DCs cluster together with
mDCs but not pDCs by genome-wide transcriptional
proﬁling. Accordingly, CD56+ DCs functionally resemble
mDCs by producing IL-12 upon TLR4 stimulation and
priming naïve T cells without prior activation. These data
suggest that the CD56+ DCs represent a novel mDC
subset mixed with some pDC features. A CD4+CD56+
hematological malignancy was classiﬁed as blastic
plasmacytoid dendritic cell neoplasm (BPDCN) due to
its expression of characteristic molecules of pDCs.
However, we demonstrated that BPDCN is closer to
CD56+ DCs than pDCs by global gene-expression pro-
ﬁling. Thus, we propose that the CD4+CD56+ neoplasm
may be a tumor counterpart of CD56+ mDCs but not
pDCs.
KEYWORDS dendritic cells, CD56+ DC, pDC, mDC,
BPDCN
INTRODUCTION
Dendritic cells (DCs) are professional antigen-presenting
cells found in virtually all tissues. The main function of DCs is
to induce T-cell activation, polarization and expansion
against invading pathogens while maintaining tolerance to
self antigens (Steinman, 2007). Three DC subsets have
been identiﬁed in the human blood: plasmacytoid dendritic
cell (pDC) and two subsets of myeloid DC (mDC) expressing
CD1c (BDCA1) and CD141 (BDCA3) respectively (Dzionek
et al., 2000; Ziegler-Heitbrock et al., 2010). pDCs are char-
acterized by their speciﬁc expression of CD123, BDCA2,
BDCA4 and ILT7 (Dzionek et al., 2000; Cao et al., 2006;
Rissoan et al., 2002). In addition, pDCs express high levels
of interferon regulatory factor 7 (IRF7), Toll like receptor
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(TLR)-7 and TLR-9. Accordingly, they produce large
amounts of type I interferon (IFN-I) upon stimulation with
nucleic-acid ligands of TLR7/TRL9 (Siegal et al., 1999; Cella
et al., 1999). Transcription factors E2-2 and Spi B are
speciﬁcally expressed in pDCs and play important roles in
their development and maintenance (Cisse et al., 2008;
Schotte et al., 2004).
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is
a rare hematological malignancy characterized by the clonal
proliferation of pDC-like cells (Facchetti et al., 2008). Neo-
plastic cells from BPDCN patients express pDC speciﬁc
molecules, such as BDCA2, CD123, CD4, TCL1, Bcl11A,
CD2AP and Spi B (Petrella and Facchetti, 2010). Addition-
ally, BPDCN cells can produce IFN-I upon TLR7 and TLR9
ligands stimulation although at much lower level comparing
with pDCs (Chaperot et al., 2001). Interestingly, BPDCN
cells also express CD56, which is not present on the majority
of pDCs (Grouard et al., 1997). A small population of DCs in
normal or FLT3 mobilized human blood do express CD56,
which have been proposed as a pDC subpopulation that
gives rise to BPDCN (Petrella et al., 2002; Comeau, 2002).
In this report, we characterized these BDCA2+
CD123+CD56+ DCs from human peripheral blood. Although
they express some pDC featured molecules, the transcrip-
tomic and functional characterizations indicate that they
belong to mDCs rather than pDCs.
RESULTS
CD56+ DCs are functionally distinct from pDCs
BDCA2 and CD123 are commonly used for the identiﬁcation
of human pDCs in the blood and lymphoid tissues. A sub-
population of BDCA2+CD123+CD56+ (CD56+) DCs have
been reported in human blood and proposed as a pDC
subpopulation related to BPDCN (Petrella et al., 2002;
Comeau, 2002). We ﬁrst conﬁrmed the presence of CD56+
subset in the HLA-DR+, CD11c−, BDCA2+ and CD123+ DCs
in human blood (Fig. 1A and 1B). The CD56+ subset rep-
resents about 5% of the BDCA2 and CD123 double positive
cells (Fig. 1B, n = 15). It was reported that pDCs can be
divided into two populations by their CD2 expression (Matsui
et al., 2009). We found that the CD56+ DCs universally ex-
press CD2 (Fig. 2A).
Next, we puriﬁed the CD56+ and CD56− cells to compare
their IFN-I production by TLR7 or TLR9 stimulation. In order
to get higher purity, we added CD2 in our puriﬁcation pro-
tocol, thus CD123+CD2+CD56+ and CD123+CD2−CD56−
DCs were sorted by FACS for further analysis. Usually the
purity of CD2−CD56− cells was over 95% and the purity of
CD2+CD56+ cells was over 80% with contamination of some
CD2+CD56− cells (Fig. 2B). High level IFNα production upon
TLR7 or TLR9 stimulation is the key characteristic of pDCs.
However, puriﬁed CD56+ DCs produced much less IFNα
upon CpG A stimulation comparing to CD56− cells from
same donors (around 10%) (Fig. 2C, left panel). Similar
results were also observed when the puriﬁed DCs were
stimulated with inﬂuenza virus (Fig. 2C, right panel). In order
to exclude the effect of CD56 antibody binding during pu-
riﬁcation, we also compared the IFNα production capacity of
CD56+ and CD56− DCs by intracellular staining without prior
puriﬁcation. When enriched DCs were stimulated with CpG A
and stained IFNα intracellularly, above 70% of CD56− cells
but only 10% CD56+ cells expressed IFNα (Fig. 2D, left
panel). Similar results were observed by R848, a TLR7 li-
gand stimulation (Fig. 2D, right panel).
CD56+ DCs clustered together with mDCs but not pDCs
by transcriptomic analysis
In order to compare the gene expression of CD56+ DCs and
other DC subsets at whole genome level, we analyzed the
transcriptome of both CD56− pDCs and CD56+ DCs by RNA
sequencing (RNA-seq). Next, we compared the transcrip-
tional proﬁle of CD56+ DCs with cDNA array data of human
DC subsets retrieved from public databases (Robbins et al.,
2008). There were 772 genes expressed in CD56+ DCs at
higher level (over 2 times) than those of CD56− DCs and
2398 genes vice versa. Among those, 648 genes highly
expressed in CD56+ cells (Fig. 3A, left panel) and 1557 lowly
expressed ones (Fig. 3B, left panel) were present in the
cDNA array data of human blood DC subsets (Robbins et al.,
2008). And the names of those differentially expressed ge-
nes are provided in Table S1 and S2. Intriguingly, 547 (91%)
CD56+ DC highly expressed genes present at higher level in
mDCs than pDCs based on cDNA array data (Fig. 3A, right
panel; Table S1). Similarly, 1292 (83%) CD56+ DCs lowly
expressed genes presented at lower level in mDCs than
pDCs (Fig. 3B, right panel; Table S2).
To clarify the relationship of CD56+ DCs and other DC
subsets, we normalized our RNA-Seq data with cDNA data,
then did hierarchical clustering with complete linkage and
principal component analysis (PCA) (11,372 genes). Both
analyses showed that CD56− DCs clustered together with
pDCs as expected, while the CD56+ DCs clustered together
with BDCA3 and BDCA1 mDCs (Fig. 3C and 3D).
CD56+ DCs are functionally analogous to mDCs
TLR expression patterns of pDCs and mDCs are drastically
different. pDCs preferentially express TLR7 and TLR9 while
mDCs express higher levels of TLR2 and TLR4 (Liu 2005;
Cerboni et al., 2013). We found that the expression level of
TLR4 (Fig. 4A) and the amount of TNFα produced upon LPS
stimulation (Fig. 4B and 4C) were similar betweenCD56+DCs
and mDCs. Moreover, CD56+ DCs could produce IL-12 at a
comparable level to mDCs at both RNA (Fig. 4D) and protein
level (Fig. 4E). While pDCs did not produce IL-12 (Fig. 4D and
4E) as previously reported (Kadowaki et al., 2001).
Different from pDCs, mDCs could prompt T-cell prolif-
eration without prior stimulation or activation. In order to
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further characterize the relationship between CD56+ DCs,
pDCs and mDCs, we examined more gene expression that
related to antigen presentation. MHC II molecules and CD86
were highly expressed on CD56+ DCs compared to pDCs at
RNA level (Table S3). These were conﬁrmed at protein level



























































Figure 1. CD56+ DCs in human blood. (A) Human PBMC were ﬁrst gated based on light scatters, and dead cells were excluded by
yellow ﬂuorescent reactive dye (L/D dye), then Lin−HLA-DR+BDCA2+CD123+ dendritic cells (DCs) were gated for further analysis.
(B) Gated Lin−HLA-DR+BDCA2+CD123+ blood DCs were divided into two subsets by their CD56 expression. (C) Summarized data




































































Figure 2. CD56+ DCs are functionally distinct from pDCs. (A) Human PBMC were gated on Lin−HLA-DR+CD11c−CD123+ DCs,
and the gated DCs were analyzed by their CD2 and CD56 expression. (B) Lineage depleted PBMC were gated on Lin−HLA-
DR+CD11c−CD123+ DCs, then CD2+CD56+ and CD2−CD56− DCs were sorted by FACS. The purities of sorted cells are shown in
each plot. (C) 10,000 puriﬁed CD123+CD56− and CD123+CD56+ DCs were stimulated with CpG A or inﬂuenza virus (Flu) for 24 h,
then interferon α (IFNα) in the supernatants were analyzed by ELISA. Data summarized from 3 independent donors. (D) Lineage
depleted PBMCs were stimulated with CpG A or R848 then analyzed by FACS for surface markers and IFNα intracellularly.
Lin−HLADR+CD11c−CD123+ cells were gated and plotted for CD56 and IFNα. The numbers in each quadrant represent percentage
of total gated cells. One out of four independent experiments is shown.
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lysosomal thiolreductase (GILT) is an essential enzyme for
antigen processing, (Singh and Cresswell 2010; Maric et al.,
2001) and we found that GILT and cathepsins were ex-
pressed at much higher levels in CD56+ DCs than pDCs
(Table S3). We next examined the antigen presentation by
CD56+ DCs, pDCs and mDCs. Allogeneic naïve T cells were
co-cultured with puriﬁed DCs and analyzed by tritium incor-
poration. The CD56+ DCs stimulated comparable T-cell
proliferation to mDCs, while pDCs did not induce signiﬁcant
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Figure 3. Comparing gene expression of CD56+ DCs and other DC subsets. (A) 648 genes expressed in CD123+CD56+ DCs at
least two fold higher than in CD123− CD56− DCs obtained by RNA-Seq (left panel) and their expressions in pDCs, BDCA3 mDCs and
BDCA1 mDCs extracted from cDNA array data (right panel). (B) 1557 lowly expressed genes in CD123+CD56+ relative to CD123−
CD56− DCs (left panel) and their expressions in pDCs, BDCA3 mDCs and BDCA1 mDCs extracted from cDNA array data (right
panel). (C) Clustering of CD123+CD56+ and CD123− CD56− DCs with other immune cell lineages isolated from human peripheral
blood based on their gene expression proﬁles. (D) The principal component analysis (PCA) results. Mono, monocytes; Neu,
neutrophils; NK, natural killer cells.
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CD56+ DCs are unique mDCs mixed with some pDC
features
CD56+ DCs expressed BDCA2 and CD123, which were
considered as hallmarks of pDCs (Fig. 1B). In order to further
characterize the relationship between CD56+ DCs and
pDCs, we examined more pDC-speciﬁc genes at both RNA
and protein levels in other DC subsets. And we found that
BDCA4 and ILT7, two additional pDC speciﬁc surface
markers, were expressed on CD56+ DCs but not mDCs
(Fig. 5A). Both E2-2 and SpiB, the two important transcrip-
tion factors for pDC lineage development, were expressed in
CD56+ DCs at slightly lower levels than pDCs in the RNA-
seq data (Table S4) and conﬁrmed by RT-PCR (Fig. 5B, left
two panels). It is worth to pointing out that the expression
levels of E2-2 and SpiB in CD56+ DCs were much higher
than in mDCs (Fig. 5B, left two panels). In addition, pDC
highly expressed genes IRF7, BCL11A and CD2AP
(Maraﬁoti et al., 2008) were also expressed in CD56+ DCs at
a slightly lower level compared to pDCs (Table S4). How-
ever, other pDC speciﬁc genes, such as Granzyme B,
TCL1A (Herling et al., 2003), PACSIN1 (Esashi et al., 2012)
and BAD-LAMP (Defays et al., 2011), were expressed at
least 10 times higher in pDCs than in CD56+ DCs in RNA-
seq data (Table S4).
We have already shown that CD56+ DCs produced very
low level IFNα upon CpG stimulation. And this is correlated
with the lower expression level of TLR9 in CD56+ DCs than
pDCs. However, the expression of TLR9 in CD56+ DCs
is clearly higher than in mDCs (Fig. 5B, far right panel).
Interestingly, CD56+ DCs produced comparable levels
of TNFα to those of pDCs upon CpG B stimulation
(Fig. 5C–E). These results argue that CD56+ DCs are






























































































































































































Figure 4. CD56+ DCs functionally resemble mDCs. (A) The expression of TLR4 was quantiﬁed by RT-PCR with puriﬁed DCs. Error
bars represent standard derivation from duplicated PCR samples of the same donor. Data shown are from one representative of 3
independent donors. (B) Lineage depleted PBMC were stimulated with LPS for 6 h, then the stimulated cells were collected and
stained with surface markers followed by intracellular staining of TNFα. CD123+CD56− (pDC), CD123+CD56+ (CD56+) and CD123−
CD11C+ (mDC) in the Lin− HLA-DR+ gate were analyzed for TNFα expression. (C) Summarized data of (B) from 5 independent
donors. (D) Puriﬁed DCs were stimulated with mixture of LPS, CpG and IFNγ for 6 h, the expression of IL-12 p35 and p40 were
analyzed by RT-PCR. Data shown are representative of 3 independent experiments. (E) Puriﬁed DCs were stimulated mixture of
LPS, CpG and IFNγ for 24 h, and the expression of IL-12 p70 were analyzed by ELISA. Data shown are representative of 2
independent experiments. (F) Expression of HLA-DR and CD86 on different blood DC subsets were analyzed by FACS. (G) Puriﬁed
allogenic naive T cells were cocultured with different numbers of CD123+CD56− (pDC, circle), CD123+CD56+ (CD56+, square) and
CD123−CD11C+ (mDC, triangle) DCs . After 5 days, the cocultured cells were pulsed with 1 mCi [3H] thymidine for 18 h before
harvest. Data shown are one representative of 4 experiments.
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BPDCN is closely related to CD56+ DCs, but not pDCs
by global gene expression proﬁling
In a previous report, we have found that BPDCN shows both
myeloid and pDC characteristics (Cerboni et al., 2013). In
order to clarify the relationship among BPDCN, pDC and
CD56+ DCs, we analyzed the differentially expressed genes
between BPDCN and pDCs. We identiﬁed 127 genes ex-
press at higher levels in BPDCN than in pDC in cDNA array
data (Fig. 6A, left panel; Table S7), but 93 (73%) of them are
highly expressed in CD56+ DCs compared to pDCs in our
RNA-seq data (Fig. 6A, right panel). Similarly, there are 1143
genes expressed at lower levels in BPDCN cells than in
pDCs (Fig. 6B, left panel; Table S8), and 778 (68%) of them
are highly expressed in the CD56+ DCs than pDCs (Fig. 6B,
right panel). The global gene expression proﬁling data sug-
gests that BPDCN is more closely related to the CD56+ DCs
than pDCs.
DISCUSSION
CD4+CD56+ hematologic malignancy with primary cuta-
neous presentation has been well documented and is pro-
posed as the malignant counterpart of pDC precursors
(Chaperot et al., 2001; Adachi et al., 1994; Brody 1995;
Uchiyama 1998; Petrella et al., 1999) and was named as
blastic plasmacytoid dendritic cell neoplasm (BPDCN)
(Facchetti et al., 2008). Here in this report, we characterized
a BDCA2+CD123+CD56+ blood DC subset, which has been
considered as a subpopulation of pDCs (Petrella et al.,
2002). We demonstrated that the CD56+ DCs clustered with
mDCs by transcriptional proﬁling at whole genome level.
Accordingly, CD56+ DCs responded to TLR4 stimulation and
prime naïve T cells without prior stimulation. And this agrees
with our previous ﬁnding that BPDCN are characterized by
their mixed pDC and myeloid signature (Sapienza et al.,











































































































Figure 5. CD56+ DCs adopt certain characteristics attributed to pDCs. (A) The expression of BDCA4 and ILT7 in different DC
subpopulations from PBMC were analyzed by FACS. Data shown are one representative of 3 donors. (B) CD123+CD56− (pDC),
CD123+CD56+ (CD56+) and CD123−CD11C+ (mDC) were puriﬁed from PBMC, E2-2, Spi-B and TLR9 expression in those three DC
populations were analyzed by RT-PCR. Error bars represent standard derivation from duplicated PCR samples of same donor. Data
shown are one representative of 3 donors. (C) Puriﬁed DCs were stimulated with CpG B for 24 h, and the expression of TNFα were
analyzed by ELISA. Data shown are summarized from 3 independent experiments. (D) Lineage depleted PBMCs were stimulated
with CpG B for 6 h, then stimulated cells were collected and stained with Lin, HLA-DR, CD123, CD11C and CD56 followed by
intracellular staining of TNFα. The Lin− HLA-DR+ cells were divided into CD123+CD56− (pDC), CD123+CD56+ (CD56+) and CD123−
CD11C+ (mDC) subsets, TNFα expression in each DC subset were analyzed. (E) Summarized data of (D) from 5 independent
donors.
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mDCs by expressing pDC speciﬁc molecules. Thus, we
propose that CD56+ DCs represent a unique mDC subset
and their function in immune response warrant further
characterization.
Besides BPDCN, another pDC related tumoral condition,
pDC proliferations in patients with myeloid disorders (PPMD),
has also been reported (Petrella and Facchetti 2010). The
tumor cells of BPDCN and PPDM share the common char-
acteristic phenotype of pDCs: lin−, CD4+, CD68+, CLA+,
CD123+, BDCA2+, Bcl11A+ and CD2AP+. However, CD56
expression, which is the hallmark of BPDCN, is not detected
in PPDM (Petrella and Facchetti 2010; Vermi et al., 2004).
Granzyme B (GrB) expresses at high level in pDCs (Rissoan
et al., 2002) and is also positive in PPMD (Vermi et al., 2004).
However, most reported BPDCN cases are GrB negative
(Chaperot et al., 2001; Petrella et al., 2002; Pilichowska et al.,
2007; An et al., 2013). Here in this study, we show CD56+
DCs express much lower level of GrB compared to pDC
(Table S4). We speculate that PPMD may be the tumor
counterpart of pDC, while BPDCN may represent the coun-
terpart of CD123+CD56+ DCs. This hypothesis needs to be
further investigated in the future by transcription proﬁling at
whole genome level for both DC subsets and their tumor
counterparts.
It is worth pointing out that the human CD123+CD56+ DCs
are similar to a CX3CR1
+CD8α+ mouse DC subset, which
also exhibits mixed characteristics of pDC and mDC (Ghosh
et al., 2010). The CX3CR1
+CD8α+ mouse DCs are
developmentally dependent on E2-2 and express pDC
speciﬁc genes (Spi-B, Siglec H, Bst2). However, CX3CR1
+
CD8α+ DCs do not produce IFNα upon TLR7 and TLR9
stimulation (Ghosh et al., 2010). The CX3CR1
+CD8α+ DC is
transcriptionally similar to mouse CD8− mDCs, but not to
CD8+ mDCs (Ghosh et al., 2010). The developmental rela-
tionship between human CD56+ DCs and mouse
CX3CR1
+CD8α+ DCs needs further investigation.
Taken together, we have demonstrated that human
CD56+ DCs were very close to mDC by both transcriptomic
analysis and functional characterization. Thus, we propose
that CD56+ DC should be classiﬁed as mDC, but not pDCs.
And we propose that BPDCN should be classiﬁed as mDC
but not pDC related leukemia.
MATERIALS AND METHODS
FACS analysis of DC subsets in human blood
For analysis of DC subsets in human peripheral blood, single cells
were ﬁrst gated by light scatters and dead cells were excluded by
yellow ﬂuorescent reactive live/dead cell dye staining (Life Tech-
nologies, Carlsbad, USA), then the lineage positive cells were gated
out by speciﬁc markers (CD3, CD14, CD16, CD19). HLA-
DR+CD123+BDCA2+ cells were further divided by their CD2 and
CD56 expression. Antibody stained peripheral blood mononuclear
cells (PBMC) were analyzed with LSRfortessa (BD Biosciences,
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Figure 6. Global gene expression of BPDCN, pDCs and CD56+ DCs. (A) Heat map of 127 genes highly expressed in BPDCN
comparing with pDCs by cDNA array (left panel) and their expressions in CD56+ DCs relative to CD56− pDCs by RNA-Seq (right
panel). (B) Heat map of 1143 genes highly expressed in pDCs comparing with BPDCN by cDNA array (left panel) and their
expressions in CD56+ DCs relative to CD56− pDCs by RNA-Seq (right panel).
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(DAKO, Denmark). Detailed information of antibodies used for ﬂow
cytometry analysis was shown in Table S5.
DC enrichment and in vitro stimulation
DCs were enriched by lineage (CD3, CD14, CD16, CD19) depletion,
then lineage negative cells (2 × 105 in 200 μL culture medium) were
stimulated with TLR ligands or viruses for 4 h followed by another 2 h
in the presence of Golgi Blocker (BD Biosciences, Franklin Lakes,
NJ, USA). Cells were stained with surface markers and perme-
ablized and stained with antibodies against various cytokines. TLR
ligands were purchased from Invivogen (San Diego, CA, USA)
and used at following concentrations: LPS (1 μg/mL), CpG 2216
(2 μg/mL), R848 (2 μg/mL). Heat inactivated inﬂuenza virus
A/PR8/34 was used at 10 MOI for stimulation.
DC puriﬁcation and stimulation
The lineage (CD3, CD14, CD16, CD19, CD20) depleted PBMC were
stained with HLA-DR (APC-Cy7), CD2 (PE-Cy7), CD11c (APC),
CD56 (PerCP-cy5.5) and CD123 (BV421). Lin−HLA-
DR+CD123+CD11c− CD2+CD56+ and Lin−HLA-DR+CD123+CD11c−
CD2−CD56− DCs were sorted with BD FACSAriaIII (BD Biosciences,
Franklin Lakes, NJ, USA). In some experiments, Lin−HLA-
DR+CD123−CD11c+ mDC were sorted as control. Puriﬁed DCs
(1 × 104 in 200 μL culture medium) were stimulated with different
TLR ligands at the concentration mentioned above. For IL-12 pro-
duction, puriﬁed DCs were stimulated with LPS, CpG 2006
(1 μmol/L) and IFNγ (50 ng/mL). IFNα, IL-12 and TNFα levels in the
supernatant were quantiﬁed by ELISA.
RNA-seq and data analysis
RNA extraction and sequencing were done by BGI Tech (Shenzhen,
Guangdong, China). The gene expression level was measured by
the number of uniquely mapped reads per kilobase of exon region
per million mappable reads (RPKM). The RNA-seq raw data was
aligned to the reference genome (hg19) (Trapnell et al., 2009). The
gene expressions of other cell types used in our study were obtained
from cDNA array data by Scott H Robbins (Robbins et al., 2008).
The target gene regions of microarray probes were retrieved from
the annotation ﬁle for human U133 Plus 2.0 (http://www.affymetrix.
com). To compare gene expressions from both RNA-seq and cDNA
array experiments, we only considered the reads that have at least
one nucleotide overlap with the gene regions targeted by microarray
probes. Heat maps were generated with differentially expressed
genes between CD2+CD56+ and CD2−CD56− DCs (larger than 2
times difference). Transcriptome comparison of CD2+CD56+ DCs
and other blood cells lineages were carried out with two different
mathematical methods, hierarchical clustering with complete linkage
(Eisen et al., 1998) and principal component analysis (PCA) (Alter
et al., 2000). Detailed methods of RNA-seq and data analysis were
provided in the supplemental ﬁle.
BPDCN microarray data of 6 cryopreserved tissue samples
(Sapienza et al., 2014) by Affymetrix microarray platform were nor-
malized with the rank invariant method using Lumi (Bioconductor)
(Du et al., 2008). Statistics for differential expression were applied by
Limma (Bioconductor), (Smyth 2004) and we deﬁned BPDCN sig-
niﬁcant differential expressed genes on normalized data as adjusted
P-value less than 0.05. One hundred and twenty seven BPDCN
highly expressed genes and 1143 BPDCN lowly expressed genes
were matched to our RNA-seq datasets of pDC and CD56+ DCs
(genes with RPKM less than 10 were deleted). Heat maps were
displayed using the R software.
RT-PCR
RNA was extracted from puriﬁed DCs and reverse transcribed with
Oligo dT primers. Quantitative real time PCR (RT-PCR) was per-
formed using cDNA with EF1α gene as internal control. Primers for
RT-PCR are listed in Table S6.
T-cell proliferation assay
Human CD4+CD45RA+ naïve T cells were puriﬁed from PBMC by
negative selection with magnetic beads (Miltenyi Biotech, Germany).
Different numbers of FACS puriﬁed DCs were cultured with 5 × 104
allogeneic naïve T cells in 96-well round-bottomed plates in 200 μL
culture medium. After 5 days of DC and T cell co-culture, cells were
pulsed with 1 mCi [3H]-thymidine for 18 h before harvest. Radioac-
tive uptake was measured with a TopCount NXT micro-plate scin-
tillation and luminescence counter (PerkinElmer).
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